Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 28, 2019 - Issue 9
Submit an article Journal homepage
359
Views
12
CrossRef citations to date
0
Altmetric
Drug Evaluation

TTP399: an investigational liver-selective glucokinase (GK) activator as a potential treatment for type 2 diabetes

Aoife EganDivision of Endocrinology and Diabetes, Diabetes and Metabolism Department of Medicine, Rochester, MN, USAView further author information
&
Adrian VellaDivision of Endocrinology and Diabetes, Diabetes and Metabolism Department of Medicine, Rochester, MN, USACorrespondence[email protected]
View further author information
Pages 741-747 | Received 17 Apr 2019, Accepted 08 Aug 2019, Published online: 16 Aug 2019

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Yixin Ren, Li Li, Li Wan, Yan Huang & Shuang Cao. (2022) Glucokinase as an emerging anti-diabetes target and recent progress in the development of its agonists. Journal of Enzyme Inhibition and Medicinal Chemistry 37:1, pages 606-615.
Read now
Xolani H Makhoba, Claudio Viegas Jr, Rebamang A Mosa, Flávia P D Viegas & Ofentse J Pooe. (2020) Potential Impact of the Multi-Target Drug Approach in the Treatment of Some Complex Diseases. Drug Design, Development and Therapy 14, pages 3235-3249.
Read now

Articles from other publishers (10)

Sweta Singh, Payel Ghosh, Shilpy Sharma, Shobha Bhargava & Ameeta Ravi Kumar. (2023) Tetrahydropalmatine from medicinal plants activates human glucokinase to regulate glucose homeostasis. Biotechnology and Applied Biochemistry.
Crossref
Sarawoot Somin, Don Kulasiri & Sandhya Samarasinghe. (2023) Alleviating the unwanted effects of oxidative stress on Aβ clearance: a review of related concepts and strategies for the development of computational modelling. Translational Neurodegeneration 12:1.
Crossref
Tobias Kroon, Therese Hagstedt, Ida Alexandersson, Annett FermMarie PeterssonStefanie Maurer, Bader ZarroukiKristina Wallenius, Nicholas D. OakesJeremie Boucher. (2022) Chronotherapy with a glucokinase activator profoundly improves metabolism in obese Zucker rats. Science Translational Medicine 14:668.
Crossref
Ajmer Singh Grewal & Viney Lather. (2022) Small Molecule Allosteric Activators of Human Glucokinase for the Treatment of Type 2 Diabetes: Current Status and Challenges. Current Drug Discovery Technologies 19:4.
Crossref
Prateek Sharma, Sukhbir Singh, Neelam Sharma, Deepak Singla, Kumar Guarve & Ajmer Singh Grewal. (2022) Targeting human Glucokinase for the treatment of type 2 diabetes: an overview of allosteric Glucokinase activators. Journal of Diabetes & Metabolic Disorders 21:1, pages 1129-1137.
Crossref
Yoshinori Tsumura, Yu Tsushima, Azusa Tamura, Hirotsugu Kato & Tsunefumi Kobayashi. (2022) Disruptions in hepatic glucose metabolism are involved in the diminished efficacy after chronic treatment with glucokinase activator. PLOS ONE 17:3, pages e0265761.
Crossref
Najeeb Shah, Mohammed Altigani Abdalla, Harshal Deshmukh & Thozhukat Sathyapalan. (2021) Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice. Therapeutic Advances in Endocrinology and Metabolism 12, pages 204201882110421.
Crossref
Zhiwei Zeng, Shi-Ying Huang & Tao Sun. (2020) Pharmacogenomic Studies of Current Antidiabetic Agents and Potential New Drug Targets for Precision Medicine of Diabetes. Diabetes Therapy 11:11, pages 2521-2538.
Crossref
Ajmer S. Grewal, Viney Lather, Neha Charaya, Neelam Sharma, Sukhbir Singh & Visvaldas Kairys. (2020) Recent Developments in Medicinal Chemistry of Allosteric Activators of Human Glucokinase for Type 2 Diabetes Mellitus Therapeutics. Current Pharmaceutical Design 26:21, pages 2510-2552.
Crossref
Konstantinos A. Toulis, Krishnarajah Nirantharakumar, Chrysa Pourzitaki, Anthony H. Barnett & Abd A. Tahrani. (2020) Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments. Drugs 80:5, pages 467-475.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.